Our findings thus suggest that while ENL inhibits cell viability and survival across multiple breast cancer subtypes, biologically relevant ENL-induced inhibition of NF-κB activity may be limited to nonluminal breast cancers, perhaps specifically to the basal-like and claudin-low subtypes. The gene discussed is NFKB1; the disease is breast cancer.